T Cell Lymphoma Drug Pipeline Analysis Report 2025
Description
According to the American Cancer Society, in the United States, T-cell lymphomas constitute approximately 15% of non-Hodgkin lymphomas. This cancer originates in the lymph tissues which are found in lymph nodes, bone marrow, spleen, adenoids and tonsils and digestive tract among others. There has been a significant emphasis on developing effective T-cell lymphoma therapeutics with major pharma companies involved in the process.
Report Coverage
The T Cell Lymphoma Pipeline Report by Expert Market Research gives comprehensive insights into T cell lymphoma drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for T-cell lymphoma. The T Cell Lymphoma pipeline insight includes the analysis of over 100 pipeline drugs and 50+ companies. It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from T-cell lymphoma.
The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing T Cell Lymphoma pipeline development activities related to T cell lymphoma are covered.
T Cell Lymphoma Drug Pipeline Outlook
Lymph tissue contains lymph, which is a colorless and watery fluid. It travels through the lymph vessels and carries lymphocytes. These white blood cells are part of the body’s immune response to infection and lymphomas originate in those white blood cells. T-cell lymphomas are rare. It occurs when certain gene changes within the white blood cells. Factors including older age, certain viral infections, and problems with the immune system are responsible for increasing the risk of non-Hodgkin lymphoma. The symptoms are based on the type of lymphoma, which includes swollen lymph nodes, weight loss, fever, night sweats, rash or itchy skin, fatigue, and pain in the chest, abdomen, and bones.
The treatment varies depending on the type and stage of cancer which includes chemotherapy, targeted therapy, immunotherapy, radiation therapy, and chemotherapy with stem cell transplantation. Chemotherapy is the main treatment for T-cell lymphomas. Targeted therapy includes monoclonal antibody therapy, which uses lab-created antibodies to destroy specific cancer cells. CAR T-cell therapy is an example of immunotherapy. Healthcare providers often do autologous stem cell transplantation in combination with chemotherapy.
Companies are developing innovative T-cell lymphoma therapeutic drugs. For instance, a phase III clinical study is going on to compare and assess the efficacy of romidepsin when administered with CHOP versus CHOP alone in patients with previously untreated peripheral T-cell lymphoma (PTCL). Several T cell lymphoma candidate drugs in the pipeline are being developed by major pharma companies which has impacted the drug pipeline for T cell lymphoma.
T Cell Lymphoma – Drug Pipeline Therapeutic Assessment
This section of the T cell lymphoma report covers the analysis of T Cell Lymphoma drugs based on various segmentations such as:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase.
EMR’s T cell lymphoma therapeutic assessment report covers 50+ drug analyses based on drug classes:
EMR’s T cell lymphoma clinical assessment report covers 50+ drug analyses based on the route of administration.
The T cell lymphoma report assessment covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials, with approximately 1,000+ trials currently in phase II.
T Cell Lymphoma – Pipeline Assessment Segmentation, By Drug Class
The drug class categories covered under T cell lymphoma pipeline analysis include oligonucleotide, peptide, and small molecule. Antisense oligonucleotides are next-generation drugs which treat disease by blocking the transfer of harmful messages from the genes. In the case of cancer, these drugs help in blocking messages that encourage the tumor spread. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for T cell lymphoma.
T Cell Lymphoma Clinical Trials Assessment – Competitive Dynamics
The EMR T cell lymphoma report insights involve the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in T cell lymphoma clinical trials:
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for T cell lymphoma. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of T cell lymphoma drug candidates.
Drug: Lenalidomide
Lenalidomide is currently under phase II and is sponsored by Celgene. The study is conducted to assess the effects of oral lenalidomide monotherapy administered to patients with relapsed or refractory T-cell lymphoma.
BMS-986369
A phase II study, sponsored by Bristol-Myers Squibb is being conducted to evaluate the safety, effectiveness, and tolerability of the T cell lymphoma drug candidate in patients with relapsed or refractory T-cell lymphomas in Japan.
Isatuximab SAR650984
Sanofi is developing the drug and is currently under phase II. The study is investigating the safety profile, duration of response, and pharmacokinetics (PK) of isatuximab in participants with T-ALL.
Reasons To Buy This Report
The T Cell Lymphoma Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for T cell lymphoma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into T cell lymphoma collaborations, market trends, regulatory environments, and potential growth opportunities within T cell lymphoma pipeline insights.
Key Questions Answered in the T Cell Lymphoma – Pipeline Assessment Report
Hodgkin’s Lymphoma Treatment Market
Acute Lymphoblastic Leukemia Therapeutics Market
Australia and New Zealand Cutaneous T-cell Lymphoma Market
Report Coverage
The T Cell Lymphoma Pipeline Report by Expert Market Research gives comprehensive insights into T cell lymphoma drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for T-cell lymphoma. The T Cell Lymphoma pipeline insight includes the analysis of over 100 pipeline drugs and 50+ companies. It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from T-cell lymphoma.
The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing T Cell Lymphoma pipeline development activities related to T cell lymphoma are covered.
T Cell Lymphoma Drug Pipeline Outlook
Lymph tissue contains lymph, which is a colorless and watery fluid. It travels through the lymph vessels and carries lymphocytes. These white blood cells are part of the body’s immune response to infection and lymphomas originate in those white blood cells. T-cell lymphomas are rare. It occurs when certain gene changes within the white blood cells. Factors including older age, certain viral infections, and problems with the immune system are responsible for increasing the risk of non-Hodgkin lymphoma. The symptoms are based on the type of lymphoma, which includes swollen lymph nodes, weight loss, fever, night sweats, rash or itchy skin, fatigue, and pain in the chest, abdomen, and bones.
The treatment varies depending on the type and stage of cancer which includes chemotherapy, targeted therapy, immunotherapy, radiation therapy, and chemotherapy with stem cell transplantation. Chemotherapy is the main treatment for T-cell lymphomas. Targeted therapy includes monoclonal antibody therapy, which uses lab-created antibodies to destroy specific cancer cells. CAR T-cell therapy is an example of immunotherapy. Healthcare providers often do autologous stem cell transplantation in combination with chemotherapy.
Companies are developing innovative T-cell lymphoma therapeutic drugs. For instance, a phase III clinical study is going on to compare and assess the efficacy of romidepsin when administered with CHOP versus CHOP alone in patients with previously untreated peripheral T-cell lymphoma (PTCL). Several T cell lymphoma candidate drugs in the pipeline are being developed by major pharma companies which has impacted the drug pipeline for T cell lymphoma.
T Cell Lymphoma – Drug Pipeline Therapeutic Assessment
This section of the T cell lymphoma report covers the analysis of T Cell Lymphoma drugs based on various segmentations such as:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase.
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
EMR’s T cell lymphoma therapeutic assessment report covers 50+ drug analyses based on drug classes:
- Oligonucleotide
- Peptide
- Small Molecule
EMR’s T cell lymphoma clinical assessment report covers 50+ drug analyses based on the route of administration.
- Oral
- Parenteral
- Others
The T cell lymphoma report assessment covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials, with approximately 1,000+ trials currently in phase II.
T Cell Lymphoma – Pipeline Assessment Segmentation, By Drug Class
The drug class categories covered under T cell lymphoma pipeline analysis include oligonucleotide, peptide, and small molecule. Antisense oligonucleotides are next-generation drugs which treat disease by blocking the transfer of harmful messages from the genes. In the case of cancer, these drugs help in blocking messages that encourage the tumor spread. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for T cell lymphoma.
T Cell Lymphoma Clinical Trials Assessment – Competitive Dynamics
The EMR T cell lymphoma report insights involve the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in T cell lymphoma clinical trials:
- Celgene
- Hebei Senlang Biotechnology Inc., Ltd.
- Bristol-Myers Squibb
- CRISPR Therapeutics AG
- Legend Biotech USA Inc.
- Eisai Inc.
- Takeda
- Corvus Pharmaceuticals, Inc.
- Rhizen Pharmaceuticals SA
- Antengene Corporation
- Rigel Pharmaceuticals
- iCell Gene Therapeutics
- Dizal Pharmaceuticals
- SciTech Development, LLC
- Jiangsu HengRui Medicine Co., Ltd.
- Sanofi
- Others
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for T cell lymphoma. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of T cell lymphoma drug candidates.
Drug: Lenalidomide
Lenalidomide is currently under phase II and is sponsored by Celgene. The study is conducted to assess the effects of oral lenalidomide monotherapy administered to patients with relapsed or refractory T-cell lymphoma.
BMS-986369
A phase II study, sponsored by Bristol-Myers Squibb is being conducted to evaluate the safety, effectiveness, and tolerability of the T cell lymphoma drug candidate in patients with relapsed or refractory T-cell lymphomas in Japan.
Isatuximab SAR650984
Sanofi is developing the drug and is currently under phase II. The study is investigating the safety profile, duration of response, and pharmacokinetics (PK) of isatuximab in participants with T-ALL.
Reasons To Buy This Report
The T Cell Lymphoma Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for T cell lymphoma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into T cell lymphoma collaborations, market trends, regulatory environments, and potential growth opportunities within T cell lymphoma pipeline insights.
Key Questions Answered in the T Cell Lymphoma – Pipeline Assessment Report
- What is the current landscape of T cell lymphoma pipeline drugs?
- Which companies/institutions are developing T cell lymphoma emerging drugs?
- How many phase II drugs are currently present in T cell lymphoma pipeline drugs?
- Which company is leading the T cell lymphoma pipeline development activities?
- What is the current T cell lymphoma therapeutic assessment?
- What are the opportunities and challenges present in the T cell lymphoma drug pipeline landscape?
- What is the efficacy and safety profile of T cell lymphoma pipeline drugs?
- Which companies/institutions are involved in T cell lymphoma collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in T cell lymphoma?
Hodgkin’s Lymphoma Treatment Market
Acute Lymphoblastic Leukemia Therapeutics Market
Australia and New Zealand Cutaneous T-cell Lymphoma Market
Table of Contents
200 Pages
- 1 Preface
- 1.1 Introduction
- 1.2 Objectives of the Study
- 1.3 Research Methodology and Assumptions
- 2 Executive Summary
- 3 Overview of T Cell Lymphoma
- 3.1 Signs and Symptoms
- 3.2 Causes
- 3.3 Risk Factors
- 3.4 Diagnosis
- 3.5 Treatment
- 4 Patient Profile
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 T Cell Lymphoma: Epidemiology Snapshot
- 5.1 T Cell Lymphoma Incidence by Key Markets
- 5.2 T Cell Lymphoma– Patients Seeking Treatment in Key Markets
- 6 T Cell Lymphoma: Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 7 T Cell Lymphoma: Key Facts Covered
- 7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
- 7.2 Top Countries Contributing to Clinical Trials in Europe
- 7.3 Top Countries Contributing to Clinical Trials in North America
- 7.4 Top Countries Contributing to Clinical Trials in Other Regions
- 8 T Cell Lymphoma, Drug Pipeline Assessment
- 8.1 Assessment by Treatment Type
- 8.2 Assessment by Route of Administration
- 8.3 Assessment by Drug Class
- 9 EMR Drug Pipeline Comparative Analysis
- 9.1 List of T Cell Lymphoma Pipeline Drugs
- 9.1.1 By Company
- 9.1.2 By Phase
- 9.1.3 By Indication
- 9.1.4 By Trial Status
- 9.1.5 By Funder Type
- 9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
- 10 T Cell Lymphoma Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
- 10.1 Comparative Analysis for Late-Stage Drugs
- 10.1.1 Study Type
- 10.1.2 Recruitment Status
- 10.1.3 Company
- 10.1.4 Funder Type
- 10.2 Product Level Analysis*
- 10.2.1 Brentuximab vedotin
- 10.2.1.1 Product Description
- 10.2.1.2 Trial ID
- 10.2.1.3 Sponsor Name
- 10.2.1.4 Study Type
- 10.2.1.5 Drug Class
- 10.2.1.6 Eligibility Criteria
- 10.2.1.7 Study Record Dates
- 10.2.1.7.1 First Submitted
- 10.2.1.7.2 First Posted
- 10.2.1.7.3 Last Update Posted
- 10.2.1.7.4 Last Verified
- 10.2.1.8 Indication
- 10.2.1.9 Study Design
- 10.2.1.10 Recruitment Status
- 10.2.1.11 Enrollment (Estimated)
- 10.2.1.12 Location Countries
- 10.2.1.13 Recent Results
- 10.2.2 Azacitidine
- 10.2.3 Pralatrexate
- 10.2.4 Other Drug
- 11 T Cell Lymphoma Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
- 11.1 Comparative Analysis for Mid-Stage Drugs
- 11.1.1 Study Type
- 11.1.2 Recruitment Status
- 11.1.3 Company
- 11.1.4 Funder Type
- 11.2 Product Level Analysis*
- 11.2.1 LIS1
- 11.2.1.1 Product Description
- 11.2.1.2 Trial ID
- 11.2.1.3 Sponsor Name
- 11.2.1.4 Study Type
- 11.2.1.5 Drug Class
- 11.2.1.6 Eligibility Criteria
- 11.2.1.7 Study Record Dates
- 11.2.1.7.1 First Submitted
- 11.2.1.7.2 First Posted
- 11.2.1.7.3 Last Update Posted
- 11.2.1.7.4 Last Verified
- 11.2.1.8 Indication
- 11.2.1.9 Study Design
- 11.2.1.10 Recruitment Status
- 11.2.1.11 Enrollment (Estimated)
- 11.2.1.12 Location Countries
- 11.2.1.13 Recent Results
- 11.2.2 Alemtuzumab (Campath-1H)
- 11.2.3 Other Drugs
- 12 T Cell Lymphoma Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
- 12.1 Comparative Analysis for Early-Stage Drugs
- 12.1.1 Study Type
- 12.1.2 Recruitment Status
- 12.1.3 Company
- 12.1.4 Funder Type
- 12.2 Product Level Analysis*
- 12.2.1 LB1901
- 12.2.1.1 Product Description
- 12.2.1.2 Trial ID
- 12.2.1.3 Sponsor Name
- 12.2.1.4 Study Type
- 12.2.1.5 Drug Class
- 12.2.1.6 Eligibility Criteria
- 12.2.1.7 Study Record Dates
- 12.2.1.7.1 First Submitted
- 12.2.1.7.2 First Posted
- 12.2.1.7.3 Last Update Posted
- 12.2.1.7.4 Last Verified
- 12.2.1.8 Indication
- 12.2.1.9 Study Design
- 12.2.1.10 Recruitment Status
- 12.2.1.11 Enrollment (Estimated)
- 12.2.1.12 Location Countries
- 12.2.2 CPI-818
- 12.2.3 Tenalisib
- 12.2.4 Other Drugs
- 13 T Cell Lymphoma Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
- 13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
- 13.1.1 Study Type
- 13.1.2 Recruitment Status
- 13.1.3 Company
- 13.1.4 Funder Type
- 13.2 Product Level Analysis*
- 13.2.1 PEG-L-Asparaginase
- 13.2.1.1 Product Description
- 13.2.1.2 Trial ID
- 13.2.1.3 Sponsor Name
- 13.2.1.4 Study Type
- 13.2.1.5 Drug Class
- 13.2.1.6 Eligibility Criteria
- 13.2.1.7 Study Record Dates
- 13.2.1.7.1 First Submitted
- 13.2.1.7.2 First Posted
- 13.2.1.7.3 Last Update Posted
- 13.2.1.7.4 Last Verified
- 13.2.1.8 Indication
- 13.2.1.9 Study Design
- 13.2.1.10 Recruitment Status
- 13.2.1.11 Enrollment (Estimated)
- 13.2.1.12 Location Countries
- 13.2.2 CTA30X UCAR-T
- 13.2.3 Other Drugs
- 14 T Cell Lymphoma, Key Drug Pipeline Companies
- 14.1 Celgene
- 14.1.1 Company Snapshot
- 14.1.2 Pipeline Product Portfolio
- 14.1.3 Financial Analysis
- 14.1.4 Recent News and Developments
- 14.2 Hebei Senlang Biotechnology Inc., Ltd.
- 14.2.1 Company Snapshot
- 14.2.2 Pipeline Product Portfolio
- 14.2.3 Financial Analysis
- 14.2.4 Recent News and Developments
- 14.3 Bristol-Myers Squibb
- 14.3.1 Company Snapshot
- 14.3.2 Pipeline Product Portfolio
- 14.3.3 Financial Analysis
- 14.3.4 Recent News and Developments
- 14.4 CRISPR Therapeutics AG
- 14.4.1 Company Snapshot
- 14.4.2 Pipeline Product Portfolio
- 14.4.3 Financial Analysis
- 14.4.4 Recent News and Developments
- 14.5 Legend Biotech USA Inc.
- 14.5.1 Company Snapshot
- 14.5.2 Pipeline Product Portfolio
- 14.5.3 Financial Analysis
- 14.5.4 Recent News and Developments
- 14.6 Eisai Inc.
- 14.6.1 Company Snapshot
- 14.6.2 Pipeline Product Portfolio
- 14.6.3 Financial Analysis
- 14.6.4 Recent News and Developments
- 14.7 Takeda
- 14.7.1 Company Snapshot
- 14.7.2 Pipeline Product Portfolio
- 14.7.3 Financial Analysis
- 14.7.4 Recent News and Developments
- 14.8 Corvus Pharmaceuticals, Inc.
- 14.8.1 Company Snapshot
- 14.8.2 Pipeline Product Portfolio
- 14.8.3 Financial Analysis
- 14.8.4 Recent News and Developments
- 14.9 Rhizen Pharmaceuticals SA
- 14.9.1 Company Snapshot
- 14.9.2 Pipeline Product Portfolio
- 14.9.3 Financial Analysis
- 14.9.4 Recent News and Developments
- 14.10 Antengene Corporation
- 14.10.1 Company Snapshot
- 14.10.2 Pipeline Product Portfolio
- 14.10.3 Financial Analysis
- 14.10.4 Recent News and Developments
- 14.11 Rigel Pharmaceuticals
- 14.11.1 Company Snapshot
- 14.11.2 Pipeline Product Portfolio
- 14.11.3 Financial Analysis
- 14.11.4 Recent News and Developments
- 14.12 iCell Gene Therapeutics
- 14.12.1 Company Snapshot
- 14.12.2 Pipeline Product Portfolio
- 14.12.3 Financial Analysis
- 14.12.4 Recent News and Developments
- 14.13 Dizal Pharmaceuticals
- 14.13.1 Company Snapshot
- 14.13.2 Pipeline Product Portfolio
- 14.13.3 Financial Analysis
- 14.13.4 Recent News and Developments
- 14.14 SciTech Development, LLC
- 14.14.1 Company Snapshot
- 14.14.2 Pipeline Product Portfolio
- 14.14.3 Financial Analysis
- 14.14.4 Recent News and Developments
- 14.15 Jiangsu HengRui Medicine Co., Ltd.
- 14.15.1 Company Snapshot
- 14.15.2 Pipeline Product Portfolio
- 14.15.3 Financial Analysis
- 14.15.4 Recent News and Developments
- 14.16 Sanofi
- 14.16.1 Company Snapshot
- 14.16.2 Pipeline Product Portfolio
- 14.16.3 Financial Analysis
- 14.16.4 Recent News and Developments
- 15 Regulatory Framework for Drug Approval, By Region
- 16 Terminated or Suspended Pipeline Products
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
